Antonia Digklia, Ioannis A Voutsadakis, Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland.
World J Gastrointest Oncol. 2013 May 15;5(5):88-96. doi: 10.4251/wjgo.v5.i5.88.
Squamous cell carcinoma, one of the two major sub-types of esophageal carcinomas, constitutes the great majority of tumors in the upper and middle third of the organ. Declining in incidence in western countries, it continues to be a significant public health problem in the far east. Targeted treatments are novel therapies introduced in the clinical therapeutic armamentarium of oncology in the last 10-15 years. They represent a rational way of treating various cancers based on their molecular lesions. Although no such agent has been approved so far for the treatment of esophageal squamous cell carcinomas (ESCC), several are in clinical trials and several others have displayed pre-clinical activity that would justify the efforts and risks of pursuing their clinical development in this disease. This paper discusses some of these targeted agents in more advanced development in metastatic ESCC, as well as some promising drugs with pre-clinical or initial clinical data in the disease.
鳞状细胞癌是食管癌的两个主要亚型之一，构成了食管中上段的大多数肿瘤。在西方国家发病率下降的同时，它在远东仍然是一个重大的公共卫生问题。靶向治疗是过去 10-15 年引入肿瘤学临床治疗武器库的新型疗法。它们代表了一种基于分子病变治疗各种癌症的合理方法。尽管到目前为止，还没有任何此类药物被批准用于治疗食管鳞状细胞癌（ESCC），但有几种药物正在临床试验中，还有几种药物在临床前显示出活性，这证明了在这种疾病中努力开发和应用这些药物的合理性和风险。本文讨论了一些在转移性 ESCC 中更先进的靶向药物，以及一些在该疾病中有临床前或初步临床数据的有前途的药物。
